Genentech, Inc.
NEWS
Roche’s Actemra failed to meet its primary and secondary endpoints in a late-stage study involving hospitalized patients with severe COVID-19 associated pneumonia.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.
Shares of Blueprint Medicines are climbing in premarket trading after the company inked a collaboration worth more than $1 billion with Genentech to develop a treatment for cancers driven by oncogenic RET alteration.
Although the trial failed to meet the primary endpoint of PFS, the data for overall survival as a co-primary endpoint is not yet mature. The company plans to continue the trial until the next planned analysis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
JOBS
IN THE PRESS